Launch GAVRETO in RET fusion-positive NSCLC in Europe
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Checked
- 24 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“launch GAVRETO in RET fusion-positive NSCLC in Europe in the first half of 2021”
What we found
Evidence strength A What the grades mean
The company did not launch GAVRETO in Europe by the first half of 2021; subsequent filings indicate the launch was pushed to the second half of 2021.
-
A Blueprint Medicines Corp 10-Q filed 2021-07-29
“If approved by the European Commission, Roche plans to launch pralsetinib in RET fusion-positive NSCLC in Europe in the second half of 2021.” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- GAVRETO launch
- Where
- Europe
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to regulatory approval
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Blueprint Medicines Corp? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C597264-021768 · Corrections policy